Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Bedossa

Showing results (261-270 of 267) with videos related to

Pageof 27
Sort By:
You have reached the last page of results.This site can display upto 267 results.
Journal of Hepatology|January 1, 2017
Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosisThomas Karlas, David Petroff, Magali Sasso, et al.
Journal of Hepatology|April 12, 2020
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statementMohammed Eslam, Philip N Newsome, Shiv K Sarin, et al.
Lancet (London, England)|December 10, 2019
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M Younossi, Vlad Ratziu, Rohit Loomba, et al.
The Lancet. Gastroenterology & Hepatology|March 23, 2023
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy studyYasaman Vali, Jenny Lee, Jerome Boursier, et al.
Hepatology (Baltimore, Md.)|March 30, 2023
Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation studyJenny Lee, Max Westphal, Yasaman Vali, et al.
Nature Metabolism|June 12, 2024
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)Michele Vacca, Ioannis Kamzolas, Lea Mørch Harder, et al.
Nature|March 25, 2021
NASH limits anti-tumour surveillance in immunotherapy-treated HCCDominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, et al.
Pageof 27

Showing results (261-270 of 267) with videos related to

Sort By:
Pageof 27
You have reached the last page of results.This site can display upto 267 results.
Journal of Hepatology|January 1, 2017
Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosisThomas Karlas, David Petroff, Magali Sasso, et al.
Journal of Hepatology|April 12, 2020
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statementMohammed Eslam, Philip N Newsome, Shiv K Sarin, et al.
Lancet (London, England)|December 10, 2019
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M Younossi, Vlad Ratziu, Rohit Loomba, et al.
The Lancet. Gastroenterology & Hepatology|March 23, 2023
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy studyYasaman Vali, Jenny Lee, Jerome Boursier, et al.
Hepatology (Baltimore, Md.)|March 30, 2023
Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation studyJenny Lee, Max Westphal, Yasaman Vali, et al.
Nature Metabolism|June 12, 2024
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)Michele Vacca, Ioannis Kamzolas, Lea Mørch Harder, et al.
Nature|March 25, 2021
NASH limits anti-tumour surveillance in immunotherapy-treated HCCDominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, et al.
Pageof 27